Abstract
Abstract Twenty-six 8-week-old specific-pathogen-free cats were vaccinated subcutaneously with 2 doses of a commercially available FeLV vaccine, and 26 age-matched specific-pathogen-free cats were similarly vaccinated with a placebo vaccine containing the same adjuvant as the FeLV vaccine. Cats then were randomly assigned to 2 groups of 26 cats (13 FeLV-vaccinated cats and 13 control cats), and each group was housed with 5 cats previously inoculated with FeLV. AU cats were tested biweekly for the next 26 weeks for evidence of FeLV antigenemia. Five of the 26 control cats developed antigenemia. However, 4 of these cats were only transiently antigénémie (positive results for 3 consecutive biweekly samples) and only 1 was persistently antigénémie. None of the FeLV-vaccinated cats developed antigenemia. Preventable fraction was calculated to be 100%.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Veterinary Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
